ULTRAGENYX PHARMACEUTICAL INC. - DEF 14A

Company

Ultragenyx Pharmaceutical Inc.

Filed

April 26, 2024

Period of Report

June 18, 2024

Accession Number

0001308179-24-000609

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →